SELLAS LIFE SCIENCES GROUP I (SLS) Stock Price, Quote, News and Overview
NASDAQ:SLS - Nasdaq - US81642T2096 - Common Stock - Currency: USD
SLS Quote, Performance and Key Statistics
NASDAQ:SLS (2/21/2025, 11:32:50 AM)
1.32
+0.01 (+0.76%)
The current stock price of SLS is 1.32 USD. In the past month the price increased by 14.91%. In the past year, price increased by 39.93%.
SLS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.99 | 357.55B | ||
| AMGN | AMGEN INC | 15.17 | 161.43B | ||
| GILD | GILEAD SCIENCES INC | 24.02 | 137.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1668.1 | 124.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.31 | 76.41B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.41B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.67B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.16B | ||
| NTRA | NATERA INC | N/A | 21.88B | ||
| BIIB | BIOGEN INC | 8.44 | 20.25B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.99B |
Related stock screener links
About SLS
Company Profile
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of novel therapeutics for a range of cancer indications. The firm's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
Company Info
SELLAS LIFE SCIENCES GROUP I
7 Times Square, Suite 2503
New York City NEW YORK 10018 US
CEO: Angelos M. Stergiou
Employees: 16
Company Website: https://www.sellaslifesciences.com/
Investor Relations: http://investors.galenabiopharma.com/investors/default.aspx
Phone: 16462005278
SELLAS LIFE SCIENCES GROUP I / SLS FAQ
What is the stock price of SELLAS LIFE SCIENCES GROUP I today?
The current stock price of SLS is 1.32 USD. The price increased by 0.76% in the last trading session.
What is the ticker symbol for SELLAS LIFE SCIENCES GROUP I stock?
The exchange symbol of SELLAS LIFE SCIENCES GROUP I is SLS and it is listed on the Nasdaq exchange.
On which exchange is SLS stock listed?
SLS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SELLAS LIFE SCIENCES GROUP I stock?
7 analysts have analysed SLS and the average price target is 5.95 USD. This implies a price increase of 350.76% is expected in the next year compared to the current price of 1.32. Check the SELLAS LIFE SCIENCES GROUP I stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SELLAS LIFE SCIENCES GROUP I worth?
SELLAS LIFE SCIENCES GROUP I (SLS) has a market capitalization of 95.81M USD. This makes SLS a Micro Cap stock.
How many employees does SELLAS LIFE SCIENCES GROUP I have?
SELLAS LIFE SCIENCES GROUP I (SLS) currently has 16 employees.
What are the support and resistance levels for SELLAS LIFE SCIENCES GROUP I (SLS) stock?
SELLAS LIFE SCIENCES GROUP I (SLS) has a support level at 1.25 and a resistance level at 1.31. Check the full technical report for a detailed analysis of SLS support and resistance levels.
Is SELLAS LIFE SCIENCES GROUP I (SLS) expected to grow?
The Revenue of SELLAS LIFE SCIENCES GROUP I (SLS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the SLS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SELLAS LIFE SCIENCES GROUP I (SLS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SLS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SLS, evaluating the profitability, health, valuation and growth aspects
- SELLAS LIFE SCIENCES GROUP I (SLS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SELLAS LIFE SCIENCES GROUP I (SLS) Sales and EPS estimates to see what analysts future expectations are.
- SELLAS LIFE SCIENCES GROUP I (SLS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SELLAS LIFE SCIENCES GROUP I (SLS) Insider and Institutional Ownership to learn about the owners and their transactions.
- SELLAS LIFE SCIENCES GROUP I (SLS) Stock Chart to make your own analysis
- SELLAS LIFE SCIENCES GROUP I (SLS) Latest news and press-releases to stay up to date.
Does SELLAS LIFE SCIENCES GROUP I (SLS) stock pay dividends?
SLS does not pay a dividend.
When does SELLAS LIFE SCIENCES GROUP I (SLS) report earnings?
SELLAS LIFE SCIENCES GROUP I (SLS) will report earnings on 2025-03-26, after the market close.
What is the Price/Earnings (PE) ratio of SELLAS LIFE SCIENCES GROUP I (SLS)?
SELLAS LIFE SCIENCES GROUP I (SLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
What is the Short Interest ratio of SELLAS LIFE SCIENCES GROUP I (SLS) stock?
The outstanding short interest for SELLAS LIFE SCIENCES GROUP I (SLS) is 13.71% of its float. Check the ownership tab for more information on the SLS short interest.
SLS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SLS. When comparing the yearly performance of all stocks, SLS is one of the better performing stocks in the market, outperforming 87.38% of all stocks.
SLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SLS. SLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SLS Financial Highlights
Over the last trailing twelve months SLS reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS increased by 55.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -227.81% | ||
| ROE | -1182.35% | ||
| Debt/Equity | 0 |
SLS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SLS. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 60.17% and a revenue growth -100% for SLS